Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses
Pharvaris (NASDAQ: PHVS) had its price target lowered by analysts at Wedbush from $35.00 to $31.00. They now have an "outperform" rating on the stock.
Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update
Pharvaris (NASDAQ: PHVS) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $34.00 price target on the stock.